DOCSLIB.ORG

Influence | Intuition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Influence | Intuition invivo.pharmaintelligence.informa.com MAY 2019 Invol. 37 ❚ no. 05 Vivopharma intelligence ❚ informa LEADERSHIPInnovation | Influence | Intuition Biotech CEOs: Can Scientist Founders Beyond The Watershed: Gene Therapy The Eye Travels Wide: ProQR’s Bid Remain In Charge? Investment And Promise For Leadership In Genetics Of Sight PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | May 2019 THE LEADERSHIP ISSUE 10 16 22 Biotech CEOs: Can Scientist- Beyond The Watershed: Rentschler Biopharma: Founders Remain In Charge? Gene Therapy Investment Growing And Innovating As MELANIE SENIOR And Promise A CDMO Business Founder-CEOs do not typically remain at JO SHORTHOUSE LUCIE ELLIS the helm as biotechs mature. Exceptions Janet Lambert, CEO of the Alliance for Frank Mathias, CEO of Rentschler to that rule are multiplying, though, Regenerative Medicine, recently spoke to Biopharma, a contract development especially in Europe as companies aim In Vivo about the tremendous levels of and manufacturing organization, talks directly for Nasdaq. investment the cell and gene therapy to In Vivo about the company’s new industries are attracting, as well as corporate strategy and why he allowed 18 26 reasons why Europe excels at incubating months to prepare that plan for delivery. advanced product development. TISSIUM CEO’s Vision Is To Make 36 The Tissue Recon Label Stick 30 ASHLEY YEO Leading In Product Develop- The Eye Travels Wide: ment Means Planning For All Christophe Bancel, CEO of French medtech innovator TISSIUM, has made a career in ProQR’s Bid For Leadership Eventualities various parts of the health care products In The Genetics Of Sight ASHLEY YEO industry, identifying business WILLIAM LOONEY What is the cost of an adverse event, and opportunities, founding, directing and How did a youthful vendor of IT services, the resulting safety action for a medical leading ventures, and planning for faced with a personal exposure to device that is already on the market? It is contingencies. The ex-Serono and UCB crippling illness, attract some of the best the kind of question that no company executive, who has had many other minds in biotech to launch a company with with products on the market wants to postings, is now testing his adaptability a then-untested RNA technology that have to confront, but it is also one they and leadership qualities by bringing a today is a contender for leadership in the know they should plan for, says the versatile class III synthetic polymer device rarified space of inherited retinal disease? design consultancy and innovation into key markets. The answer may lie in the ambitiously organization NCS Lab srl. definitive name that 35-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures. ©2016 Informa Business Information, Inc., an Informa company May 2019 | In Vivo | 1 ❚ CONTENTS In Vivo Pharma intelligence | May 2019 DEPARTMENTS ❚ From The Editor AROUND THE INDUSTRY Investors “are looking at you as an individual; how 4 New AdvaMed Chair Lobo: you think about your strategy, how you discuss Devices Have A Good Story To Tell and interact with them. They are constantly as- ASHLEY YEO sessing the team you have built around you,” one scientist-turned-CEO told In Vivo’s Melanie Senior. 5 Israel Looks To Nurture Their comments feature in a wider story focused New Leaders For Burgeoning on how and when biotech founders remain as Biotech Sector leaders of a company, and – as is more often the KEVIN GROGAN case – the events that cause them to step aside. There is a new breed of leadership in the life sci- INFOGRAPHIC: LEADERSHIP ence sector, PhD-carrying entrepreneurs who want to personally help translate their ideas into the 8 ELEANOR MALONE AND LUCIE ELLIS GAYLE REMBOLD FURBERT clinic. In this article, we explore the skills required to lead a biotech business from start-up to commercial triumph. There are sev- eral routes to success and founding members of a biotech company play differ- 40 ON THE MOVE ent roles in the journey. Still, there are challenges when it comes to the talent pool for new and emerging leadership. Recent executive appointments in the life sciences industry May’s issue also includes exclusive interviews with Frank Mathias, CEO of REGINA PALESKI Rentschler Biopharma, a contract development and manufacturing organiza- tion; Matteo Mantovani, CEO and technical director of NCS Lab srl, a certified research lab that engages in medtech lifecycle research, including design, test- 44 DEAL-MAKING ing and failure analysis; and Christophe Bancel, CEO of TISSIUM, a medtech Deals Shaping The Medical Industry, company developing an innovative polymer aimed at tissue reconstruction. March 2019 THE STRATEGIC TRANSACTIONS TEAM Elsewhere, in a discussion piece by Jo Shorthouse, Janet Lambert, CEO of the Alliance for Regenerative Medicine, highlights commercial challenges still EXCLUSIVE ONLINE CONTENT ahead for this sector even as R&D breakthroughs continue to emerge. invivo.pharmaintelligence.informa.com Finally, a different style of leadership; William Looney speaks to ProQR’s found- er and CEO Daniel de Boer about the company’s R&D strategy and making diffi- ❚ Reimagining IT: Bausch Health cult decisions. Now seven years old, and still awaiting its first marketed product, Puts Customers First In Planning ProQR does meet the criteria for standout status in emerging biotech. It has had For A Data-Driven Future a visionary founder and CEO in de Boer, driven by his family’s own exposure to incurable disease; a supportive cast of advisers from the “Dutch diaspora” of WILLIAM LOONEY world-class, business-building talent, including the late, rare disease legend Henri Termeer; and an inclusive relationship with activist patient stakeholders. ❚ Philips Plugs Into Value-Based Needs On Delirium In The ICU ASHLEY YEO ❚ Contract Disputes Trends In Vivo: Always Online First In Medtech Relevant and exclusive online-only Don’t have an online user account? DOROTHEE SCHRAMM content at your fingertips 24/7. Quickly and easily create one by clicking on the “Create your Full access to our 36-year archive. ❚ Biopharma Quarterly Deal-Making account” link at the top of the page. Access your subscription by visiting: Statistics, Q1 2019 Contact: invivo.pharmaintelligence.informa. AMANDA MICKLUS AND [email protected] com and log in. MAUREEN RIORDAN or call: (888) 670-8900 or +1 (908) 748-1221 for additional information. ❚ Deals In Depth, March 2019 All stock images in this publication courtesy of AMANDA MICKLUS /invivo @invivo /invivo www.shutterstock.com unless otherwise stated. 2 | | May 2019 invivo.pharmamedtechbi.com In Vivo invivo.pharmaintelligence.informa.com invivo.pharmaintelligence.informa.com CONTENTS ❚ ❚ Up-Front SNAPSHOTS FROM MAY’S CONTENT In today’s biopharma, the eyes have it – and the search is on for ophthalmology companies with solid science and a strong, clinically differentiated message. One start-up with a direct line of sight to both is Dutch-based ProQR Therapeutics NV. PAGE 30 There are more than 900 regenerative medicine companies worldwide. In 2018, companies active in gene 3 and cell therapies and other regenerative medicines KEY FINDINGS raised more than $13.3bn. from Rentschler for PAGE 16 CDMO evolution: Europe & Israel • quality will remain the main driver for success • communication between North America Asia clients and CDMOs needs to evolve Africa • the one-stop shop approach South America will remain favorable Oceania PAGE 22 There is a way to use failure “My goal is to be the worst investigation at an earlier stage person in my company,” in the design and development says Arnon Rosenthal, process to improve understanding serial founder and CEO. of how devices fail to perform when out in the field, and thereby avoid “If someone can be a potentially catastrophic effects. better CEO than me, PAGE 36 I’ll give them my job.” PAGE 10 ©2016 Informa Business Information, Inc., an Informa company May 2019 | In Vivo | 3 ❚ Around The Industry New AdvaMed Chair Lobo: Devices Have A Good Story To Tell CVRX CEO Nadim Yared will be a hard act to follow as AdvaMed chair, as his list of ac- Lobo has been a member of the Ad- complishments over the past two years, as well as his ability to maintain the spotlight on vaMed board since 2012, and served the medtech industry in the US and beyond, have shown. In Kevin Lobo, CEO of Stryker on its international committee between Corp., the industry has a leader who will continue to push back the boundaries for SMEs, 2015 and 2017. In Vivo’s sister publication as well as developing his own agenda points. Medtech Insight notes that he is also a board member of the influential business Lobo’s two-year tenure was announced lobby group, the Business Roundtable, on March 27, and he knows that the 2012 which comprises CEOs of leading US com- medical device excise tax will continue to panies. The group collectively represent throw a long shadow over the US industry every sector of the economy and bring a as a whole and AdvaMed’s relationship unique perspective to bear on policy is- with lawmakers in particular until it is sues that impact the markets. permanently repealed. At present, it is due to be reinstated at the end of this year. SUPPORT FOR INTERNATIONAL Meanwhile, congressional efforts INDUSTRY continue to be made to delete the tax, He is an international as well as domestic most recently in the form of the April 10 leader for the sector. For example, he introduction in the House of Representa- “We need to attract the sees the EU Medical Device Regulation tives the “Protect Medical Innovation Act of best talent from the (MDR) as a critical issue for the medtech 2019 – another step towards a permanent industry and patients in Europe.
Load more

Recommended publications
  • Giovanni Crupi
    Giovanni Crupi C U R R I C U L U M V ITAE 1 M a r c h 2017 PERSONAL DATA Birth’s city Lamezia Terme (Italy), Birth’s day 15 September 1978 Position held Tenure Track Assistant Professor at the University of Messina In February 2014 he obtained the national scientific qualification to function as associate professor in Italian Universities Affiliation BIOMORF Department, University of Messina, Messina, ITALY Phone +39-090-3977375 (office), +39-090-3977388 (lab), +39-338-3179173 (mobile) Fax +39 090 391382 E-mail [email protected] and [email protected] Skype name giocrupi EDUCATION Dec. 2006 Ph.D. degree from the University of Messina, Italy Thesis’s title: “Characterization and Modelling of Advanced GaAs, GaN and Si Microwave FETs” Advisors: Prof. Alina Caddemi (University of Messina, Italy) Prof. Dominique Schreurs (University of Leuven, Belgium) Feb. 2004 Second Level University Master in “Microwave Systems and Technologies for Telecommunications” Apr. 2003 M.S. degree in Electronic Engineering cum Laude (with Honors) from the University of Messina Thesis’s title: “Microwave PHEMT characterization and small signal modeling by direct extraction procedures” (in italian) Advisors: Prof. Alina Caddemi (University of Messina, Italy) Aug. 1997 “Diploma di maturità classica” with full grade 60/60 from the “Liceo classico- Ginnasio Pitagora” of Crotone, Italy 1 PROFESSIONAL EXPERIENCE Feb. 2014 He obtained the national scientific qualification to function as associate professor in Italian Universities Jan. 2015 – until now Tenure Track Assistant Professor at BIOMORF Department, University of Messina Jun. 2013 –Dec. 2014 Untenured Assistant Professor at “DICIEAMA” University of Messina Mar.
    [Show full text]
  • Boston University Journal of Science & Technology
    4 B.U. J. SCI. & TECH. L. 1 January 23, 1997 Boston University Journal of Science & Technology Law Symposium Financing the Biotech Industry: Can the Risks Be Reduced? Ronald Cass, Joshua Lerner, Farah H. Champsi, Stanley C. Erck, Jonathan R. Beckwith, Leslie E. Davis, Henri A. Termeer Table of Contents Speeches..........................................................................................................................[1] Dean Ronald Cass.............................................................................................[1] Joshua Lerner....................................................................................................[2] Farah Champsi..................................................................................................[8] Stanley Erck.....................................................................................................[18] Jonathan Beckwith.........................................................................................[24] Leslie Davis......................................................................................................[37] Henri Termeer.................................................................................................[47] Question and Answer Session..................................................................................[60] Financing the Biotech Industry: Can the Risks Be Reduced?† Jonathan R. Beckwith, Farah H. Champsi, Leslie E. Davis,* Stanley C. Erck, Joshua Lerner, Henri A. Termeer Dean Ronald Cass: 1. The biotechnology
    [Show full text]
  • Framework Jti
    FRAMEWORK www.unipd.it OF THE RESEARCH THE OF JTI PEOPLE AT THE UNIVERSITY OF PADOVA OF UNIVERSITY THE AT COOPERATION CAPACITIES IDEAS EURATOM AAL CIP CULTURE 2007-2014 DG HOME AFFAIRS ERANET RESEARCH FUND FOR COAL AND STEEL EUROPEAN INSTITUTE FOR GENDER EQUALITY DG JUSTICE DG HEALTH AND CONSUMERS LIFE + EUROSTARS FET FLAGSHIP FRAMEWORK OF THE RESEARCH AT THE UNIVERSITY OF PADOVA 2007-2014 2007-2014 FRAMEWORK OF THE RESEARCH AT THE UNIVERSITY OF PADOVA The great variety of projects financed by different research programmes, indicates the University’s excellent resources in most of the scientific areas. International research at the University of Padova has been particularly successful over the last year. The University now runs 196 projects within the 7th Framework Programme and almost 50 further European research programmes, supported by an overall EU contribution close to € 72 Million over the last seven years. The remarkable success of the University of Padova in the research field has been recently highlighted by the results of the national Research Quality Evaluation (VQR) carried out by the ANVUR (National Agency for the Evaluation of Universities and Research Institutes) for the period 2004-2010. The main role of the ANVUR is to assess the quality of scientific research carried out by universities as well as by public and private research institutions. The VQR results are the outcome of a huge effort by the Italian Ministry for Education, University and Research, encompassing the evaluation of 185.000 scientific products and the
    [Show full text]
  • Quantum Discrimination of Noisy Photon-Added Coherent States Stefano Guerrini , Student Member, IEEE, Moe Z
    IEEE JOURNAL ON SELECTED AREAS IN INFORMATION THEORY, VOL. 1, NO. 2, AUGUST 2020 469 Quantum Discrimination of Noisy Photon-Added Coherent States Stefano Guerrini , Student Member, IEEE, Moe Z. Win , Fellow, IEEE, Marco Chiani , Fellow, IEEE,and Andrea Conti , Senior Member, IEEE Abstract—Quantum state discrimination (QSD) is a key enabler in quantum sensing and networking, for which we envision the utility of non-coherent quantum states such as photon-added coherent states (PACSs). This paper addresses the problem of discriminating between two noisy PACSs. First, we provide representation of PACSs affected by thermal noise during state preparation in terms of Fock basis and quasi-probability distributions. Then, we demonstrate that the use of PACSs instead of coherent states can significantly reduce the error probability in QSD. Finally, we quantify the effects of phase diffusion and pho- ton loss on QSD performance. The findings of this paper reveal the utility of PACSs in several applications involving QSD. Index Terms—Quantum state discrimination, photon-added coherent state, quantum noise, quantum communications. I. INTRODUCTION Fig. 1. Illustration of binary QSD with PACSs: hypotheses are described by UANTUM STATE DISCRIMINATION (QSD) the Wigner functions corresponding to the quantum states. Q addresses the problem of identifying an unknown state among a set of quantum states [1]–[3]. QSD enables several applications including quantum communications [4]– [6], quantum sensing [7]–[9], quantum illumination [10]–[12], QSD applications. In particular, continuous-variable quantum quantum cryptography [13]–[15], quantum networks [16]– states have been considered in quantum optics as they supply [18], and quantum computing [19]–[21].
    [Show full text]
  • PERSONAL INFORMATIONS Family Name, First Name: Prof. Dr. Lenisa
    PERSONAL INFORMATIONS Family name, First name: Prof. Dr. Lenisa, Paolo Researcher unique identifier(s): orcid.org/0000-0003-3509-1240 Date of birth: June 17, 1965 Nationality: Italian EDUCATION 2014 Italian National Scientific Habilitation as Associated Professor and Full Professor in: - Experimental Physics of Fundamental Interactions - Nuclear and Sub-nuclear Physics 1997 PhD in Physics (excellent). Title of the thesis “Development of a novel laser system for laser cooling of ions in a storage ring” University of Ferrara, Ferrara, Italy 1992 Master Degree in Nuclear Engineering (summa cum laude) Politecnico di Milano, MI(IT) CURRENT POSITION Since 2017 Full professor in Nuclear and Subnuclear Physics Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, Ferrara (IT) PREVIOUS POSITIONS 2014 – 2017 Associate professor in Experimental Physics of Fundamental Interactions Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, Ferrara (IT) 1998 – 2014 Researcher Staff- Physics Department, University of Ferrara, Ferrara (IT) 1997 – 1998 Guest Scientist - Max-Planck Institut für Kernphysik, Heidelberg (D) SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS Since 2000 15 Postdocs, 11 PhDs, 20 Diploma and Master Students Department of Physics and Earth Science, University of Ferrara, Ferrara (IT) TEACHING ACTIVITIES Since 2017 Course: Subatomic Physics, Univ. of Ferrara (IT) Since 2014 Course: General Physics (Mechanics), Univ. of Ferrara, Ferrara (IT) 2015 Lecture: The history of motion and its impact on the
    [Show full text]
  • Masters Erasmus Mundus Coordonnés Par Ou Associant Un EESR Français
    Les Masters conjoints « Erasmus Mundus » Masters conjoints « Erasmus Mundus » coordonnés par un établissement français ou associant au moins un établissement français Liste complète des Masters conjoints Erasmus Mundus : http://eacea.ec.europa.eu/erasmus_mundus/results_compendia/selected_projects_action_1_master_courses_en.php *Master n’offrant pas de bourses Erasmus Mundus *ACES - Joint Masters Degree in Aquaculture, Environment and Society (cursus en 2 ans) UK-University of the Highlands and Islands LBG FR- Université de Nantes GR- University of Crete http://www.sams.ac.uk/erasmus-master-aquaculture ADVANCES - MA Advanced Development in Social Work (cursus en 2 ans) UK-UNIVERSITY OF LINCOLN, United Kingdom DE-AALBORG UNIVERSITET - AALBORG UNIVERSITY FR-UNIVERSITÉ PARIS OUEST NANTERRE LA DÉFENSE PO-UNIWERSYTET WARSZAWSKI PT-UNIVERSIDADE TECNICA DE LISBOA www.socialworkadvances.org AMASE - Joint European Master Programme in Advanced Materials Science and Engineering (cursus en 2 ans) DE – Saarland University ES – Polytechnic University of Catalonia FR – Institut National Polytechnique de Lorraine SE – Lulea University of Technology http://www.amase-master.net ASC - Advanced Spectroscopy in Chemistry Master's Course FR – Université des Sciences et Technologies de Lille – Lille 1 DE - University Leipzig IT - Alma Mater Studiorum - University of Bologna PL - Jagiellonian University FI - University of Helsinki http://www.master-asc.org Août 2016 Page 1 ATOSIM - Atomic Scale Modelling of Physical, Chemical and Bio-molecular Systems (cursus
    [Show full text]
  • Schedule 14A
    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Workshop Ferrara & Rovigo, Italy
    Workshop “Making the Circular Economy work for Sustainability: From theory to practice” Ferrara & Rovigo, Italy - February 23-25, 2021 ~ Call for Papers The Centre for Research in Circular economy, Innovation and SMEs (CERCIS) and SEEDS (Sustainability, Environmental Economics and Dynamics Studies) of the University of Ferrara are glad to announce their joint organization of an international Workshop titled Making the circular economy work for sustainability: from theory to practice The circular economy (CE) is pervasively considered and often implicitly assumed to be a novel and major avenue towards sustainability. Academic scholars and (professional and policy) practitioners are unanimously cavalier about this relationship. On a deeper scrutiny, however, the link between CE and sustainability appears weak, if not even elusive. Starting from these premises, the Workshop aims at stimulating the theoretical and empirical debate on the mechanisms that eventually enable us to establish that a relationship between CE and sustainability does actually exist, and to characterize its nature. Such a debate is crucial to achieve a deeper knowledge on how policy makers can best use the CE to promote sustainability. The Workshop will start with the official presentation of the 2020 release of the EEA (European Environment Agency) Sustainability Report, which is titled Sustainability transition in Europe in the age of demographic and technological change. Implications for fiscal revenues and financial investments. The EEA Report, to which SEEDS members have contributed, will be presented by Stefan Speck (EEA). The Workshop calls for papers on the several specificities of this broad issue, among which the following represent a non-exclusive list: the economic dividend of the circular economy; the environmental effects of the circular economy; the impacts of the circular economy on society; firms and households as main enablers of a sustainable circular economy; policies for a sustainable circular economy.
    [Show full text]
  • AVEO PHARMACEUTICALS, INC. (Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 AVEO PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials: ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Prof. Matteo Giovanni Della Porta
    Curriculum Vitae Replace with First name(s) Surname(s) PERSONAL INFORMATION Prof. Matteo Giovanni Della Porta Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University Via Manzoni, 113 - 20089 Rozzano - Milan, Italy Phone +39 02 8224 7668 Fax + 39 02 8224 4592 Mail [email protected] Web mdellaporta.com Date of birth 29/05/1974 | Nationality Italian Head, Leukemia Unit - Cancer Center - IRCCS Humanitas Research Hospital Associate professor of Hematology - Humanitas University POSITION Via Manzoni, 113 - 20089 Rozzano - Milan, Italy www.humanitas.it www.hunimed.eu WORK EXPERIENCE 2016- Head, Leukemia Unit - Cancer Center IRCCS Humanitas Research Hospital Milan, Italy & Associate Professor of Hematology – Humanitas University, Milan Italy 2014-2016 Associate Professor of Clinical Oncology – University of Pavia, Italy 2008-2015 Assistant Professor of Clinical Oncology & Consultant Hematologist, University of Pavia Italy & Department of Hematology IRCCS Policlinico San Matteo, Pavia Italy EDUCATION AND TRAINING 2003 Board Certification in Hematology - University of Ferrara, Italy 1999 Medical Degree - University of Pavia, Italy PERSONAL SKILLS Current research interests mainly concern myeloid malignancies (myelodysplastic syndromes, MDS acute myeloid leukemias AML, myeloproliferative neoplasms, MPN) These investigations led to the definition of specific gene expression profiles in myelodysplastic syndromes [Blood. 2006;108(1):337-45 and Leukemia. 2010;24(4):756-64 and J Clin Oncol 2013, J Clin Oncol. 2013 Oct 1;31(28):3557-64], to the identification of the molecular basis of refractory anemia with ringed sideroblasts associated with marked thrombocytosis [Blood. 2009;114(17):3538-45], and to the development of the WPSS [J Clin Oncol. 2007;25(23):3503-10, Blood.
    [Show full text]
  • Proqr Therapeutics N.V
    ANNUAL REPORT 2017 Meaningful progress - Excited about the future PAGE I PAGE II ANNUAL MAGAZINE 2017 ANNUAL MAGAZINE 2017 our courage to do things differently University of Colorado and during his ACCOMPLISHMENTS – and challenge the status quo. career has earned a global reputation A QUICK GLANCE We can and will make a meaningful for translating cutting-edge science impact – changing the lives of into transformational new therapies Eluforsen (formely known as QR-010) for CF patients. Be it in a small way – for rare diseases including cystic fibro- • Completed second trial for eluforsen by improving one’s quality of life. sis, pulmonary fibrosis, pulmonary • Announced positive data from Or in a big way – by stopping artery hypertension, severe immuno- Phase 1b safety and tolerability study a disease or by curing patients. logic, and inflammatory diseases. • Received FDA Fast Track designation and Orphan Drug Designation (ODD) CREATING MEANINGFUL IMPACT At ProQR, we do it all in the interest Dave is excited to be part of ProQR’s in US and Europe of patients. We’re driven, deter- management team: “ProQR has • Granted two key patents mined, excited to make this differ- a patient-centric culture committed ence. Today, tomorrow and more to transforming lives. Applying our QR-110 for LCA 10 days to come, until we get it right. RNA editing platform to precision • IND clearance from FDA and IN THE INTEREST medicine in hereditary forms of commenced Phase 1/2 safety and Building ProQR blindness, dystrophic epidermolysis efficacy trial In 2017, we made important strides bullosa, cystic fibrosis and other • First patient in trial dosed in late 2017 in ProQR’s growth.
    [Show full text]
  • Evolution on Your Dinner Plate?
    Evolution on your dinner plate? Malin Pinsky Ecology, Evolution, and Natural Resources Institute of Marine and Coastal Sciences Rutgers University The raw material for evolution DNA The raw material for evolution DNA The raw material for evolution DNA from Mother from Father Parts of the genome Gene or locus Parts of the genome Allele Source of variation • Mutations Source of variation • Mutations • Germ line copy passed to offspring Oh cruel herb of soap, Bane of burritos worldwide, The slayer of taste. from ihatecilantro.com OR6A2 gene People with two “soapy” alleles more likely than others (15% vs. 10%) to dislike cilantro Eriksson et al. 2012 Flavour Population Population Population Population • Allele frequencies – 50% blue – 50% red Phenotype: running speed Fast Slow Phenotype: running speed Fast Slow Moderate Population • Fitness: ability to pass genes on to future generations Population • Fitness: ability to pass genes on to future generations Population • Fitness: ability to pass genes on to future generations Population 33% blue 67% red • Fitness: ability to pass genes on to future generations Evolution 1. Heritable variation Evolution 1. Heritable variation 2. More offspring than can survive Evolution 1. Heritable variation 2. More offspring than can survive 3. Offspring vary in ability to survive and reproduce Bighorn sheep Coltman et al. 2003 Nature Review Trends in Ecology and Evolution Vol.23 No.6 down to thousands might have no effect on heterozygosity, Box 2. Effects of trophy hunting but could result in a decline in allelic diversity [22]. By contrast, greater harvest of males through hunting in Trophy hunting (and fishing) targets individuals with certain ungulates could have limited effect on allelic diversity desirable phenotypes [66].
    [Show full text]